Affordable Access

Access to the full text

Myeloid derived suppressor and dendritic cell subsets are related to clinical outcome in prostate cancer patients treated with prostate GVAX and ipilimumab

Authors
  • Santegoets, Saskia JAM1
  • Stam, Anita GM1, 2
  • Lougheed, Sinéad M1
  • Gall, Helen1
  • Jooss, Karin3
  • Sacks, Natalie3
  • Hege, Kristen3
  • Lowy, Israel4
  • Scheper, Rik J2
  • Gerritsen, Winald R1
  • van den Eertwegh, Alfons JM1
  • de Gruijl, Tanja D1
  • 1 VU University Medical Center, Cancer Center Amsterdam, Department of Medical Oncology, Amsterdam, The Netherlands , Amsterdam (Netherlands)
  • 2 VU University Medical Center, Cancer Center Amsterdam, Department of Pathology, Amsterdam, The Netherlands , Amsterdam (Netherlands)
  • 3 Cell Genesys Inc, South San Francisco, CA, USA , South San Francisco (United States)
  • 4 Medarex, Bloomsbury, NJ/Bristol-Myers Squibb Company, Wallingford, CT, USA , Wallingford (United States)
Type
Published Article
Journal
Journal for ImmunoTherapy of Cancer
Publisher
Springer (Biomed Central Ltd.)
Publication Date
Sep 16, 2014
Volume
2
Issue
1
Identifiers
DOI: 10.1186/s40425-014-0031-3
Source
Springer Nature
Keywords
License
Yellow

Abstract

BackgroundCancer-related disturbances in myeloid lineage development, marked by high levels of myeloid-derived suppressor cells (MDSC) and impaired dendritic cell (DC) development, are associated with poor clinical outcome due to immune escape and therapy resistance. Redressing this balance may therefore be of clinical benefit. Here we investigated the effects of combined Prostate GVAX/ipilimumab immunotherapy on myeloid subsets in peripheral blood of castration-resistant prostate cancer (CRPC) patients as well as the putative predictive value of baseline and on-treatment myeloid parameters on clinical outcome.MethodsPatients with CRPC (n?=?28) received thirteen intradermal administrations of Prostate GVAX, consisting of two allogeneic GM-CSF-transduced and irradiated prostate cancer cell lines (LN-CaP and PC3) and six infusions of escalating doses of anti-CTLA4/ipilimumab. Frequencies and activation status of peripheral blood DC (PBDC) and MDSC were determined before, during and after treatment by flowcytometric analysis and related to clinical benefit.ResultsSignificant treatment-induced activation of conventional and plasmacytoid DC subsets (cDC and pDC) was observed, which in the case of BDCA1/CD1c+ cDC1 and MDC8+/6-sulfoLacNAc+ inflammatory cDC3 was associated with significantly prolonged overall survival (OS), but also with the development of autoimmune-related adverse events. High pre-treatment levels of CD14+HLA-DR?monocytic MDSC (mMDSC) were associated with reduced OS. Unsupervised clustering of these myeloid biomarkers revealed particular survival advantage in a group of patients with high treatment-induced PBDC activation and low pretreatment frequencies of suppressive mMDSC in conjunction with our previously identified lymphoid biomarker of high pretreatment CD4+CTLA4+ T cell frequencies.ConclusionsOur data demonstrate that DC and MDSC subsets are affected by prostate GVAX/ipilimumab therapy and that myeloid profiling may contribute to the identification of patients with possible clinical benefit of Prostate GVAX/ipilimumab treatment.

Report this publication

Statistics

Seen <100 times